Drug intelligence / Profile preview

PRX-12251

Development stage: Discontinued
Lead developer: Prexa
Modality: Small Molecules
Administration: Oral

Overview

**PRX-12251** is a small molecule triple reuptake inhibitor (TRI) developed by Prexa Pharmaceuticals for central nervous system disorders. It potently blocks the dopamine transporter (DAT), sodium-dependent noradrenaline transporter (NET), and sodium-dependent serotonin transporter (SERT), with the greatest potency against DAT, aiming to enhance monoamine neurotransmitter levels in the brain for potential treatment of conditions like depression or ADHD. The program raised Series B financing in 2013 to support preclinical studies and Phase 1b trials but has since been discontinued.[1][3][5][11]

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on PRX-12251.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRX-12251.

Explore the full profile